Business Context and Reporting Period
Company: Processa Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date: March 13, 2019
Context: The registrant is an emerging growth company incorporated in Delaware. This filing serves to disclose investor presentation materials intended for use in meetings with investors and groups.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure of presentation materials rather than a financial statement.
Material Changes
No material financial changes or operational updates are detailed within the text of this specific filing. The document solely references the attachment of "Presentation Materials" (Exhibit 99.1) which speak as of the report date.
Guidance, Outlook, and Risks
- Management Commentary: The company explicitly disclaims any obligation to update the attached presentation materials in the future or to reflect events occurring after the date of this report.
- Legal Status of Information: Information contained in Item 7.01 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
- Outlook: No specific financial guidance or operational outlook is provided in the text of this filing.
Investor Verification Checklist
- Review the attached Exhibit 99.1 (Investor Presentation dated March 13, 2019) for actual financial data and strategic updates, as the 8-K text only references it.
- Verify the company's status as an "emerging growth company" and its implications for financial reporting standards.
- Note that the presentation materials are not legally "filed" and the company has no obligation to update them.
- Confirm the identity of the signatory, David Young, Chief Executive Officer.